Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Catheter Precision, Inc. (NYSEAMERICAN:VTAK) saw a large decrease in short interest in September. As of September 15th, there was short interest totaling 228,199 shares, a decrease of 42.8% from the August 31st total of 398,714 shares. Based on an average trading volume of 934,294 shares, the short-interest ratio is presently 0.2 days. Approximately 1.7% of the shares of the stock are short sold.

Catheter Precision Stock Up 4.9%

Shares of NYSEAMERICAN:VTAK traded up $0.01 during midday trading on Wednesday, hitting $0.15. 838,612 shares of the company’s stock traded hands, compared to its average volume of 1,541,009. The company has a market cap of $2.16 million, a PE ratio of -0.02 and a beta of -1.03. The firm’s fifty day moving average price is $0.22 and its two-hundred day moving average price is $0.69. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.18 and a current ratio of 0.19. Catheter Precision has a twelve month low of $0.13 and a twelve month high of $3.20.

Catheter Precision’s stock is going to reverse split before the market opens on Monday, October 5th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, October 4th.

Catheter Precision (NYSEAMERICAN:VTAK) last announced its earnings results on Friday, August 14th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($19.00) by $18.08. Catheter Precision had a negative net margin of 656.03% and a negative return on equity of 37.53%. The company had revenue of $1.02 million for the quarter, compared to analyst estimates of $2.00 million.

Catheter Precision Company Profile

Catheter Precision, Inc is a medical device company focused on developing technologies for electrophysiology procedures used to diagnose and treat cardiac arrhythmias. Its products are designed to support physicians during catheter-based cardiac procedures, particularly those involving ventricular arrhythmias.

The company’s portfolio includes the VIVO system, a noninvasive cardiac mapping platform intended to help physicians identify the origin of ventricular arrhythmias and plan catheter ablation procedures.